Mutations in the calcium-sensing receptor gene (CaSR) may result in disorders of calcium homeostasis manifesting as familial benign hypocalciuric hypercalcaemia (FBHH), neonatal severe hyperparathyroidism (NSHPT) or autosomal dominant hypocalcaemia with hypercalciuria (ADHH). FBHH may have a population prevalence as high as one in 16 000, and ADHH one in 70 000. NSHPT is very rare.
Introduction
The calcium-sensing receptor (CaSR) plays an essential role in calcium homeostasis. It is a cell surface protein (1078 amino acids) with a large extra-cellular domain, seven transmembrane domains and an intracytoplasmic tail. The CaSR messenger RNA is expressed in parathyroid chief cells, allowing calciumresponsive parathyroid hormone (PTH) release, and in the thick ascending limb of the loop of Henle and the distal nephron allowing calcium-responsive renal tubular calcium re-absorption. Activation of CaSR leads to an intracellular accumulation of inositol 1, 4, 5, triphosphate and transient intracellular calcium release. In the parathyroid cell, this has the e¡ect of reducing PTH secretion on the cell surface, and so a rise in plasma calcium concentration inhibits PTH secretion. In the renal tubular cell, the e¡ect is reduction of calcium resorption, and thus promotion of calcium excretion. The CaSR gene is located on the short arm of chromosome 3p13.3-21, (OMIM reference 601199 CALCIUM-SENSING RECEPTOR; CaSR). Inherited abnormalities of the CaSR gene can cause either hypercalcaemia or hypocalcaemia. Heterozygous loss-of-function mutations give rise to familial benign hypocalciuric hypercalcaemia (FBHH) and heterozygous gain-of-function mutations result in autosomal dominant hypocalcaemia with Review Article hypercalciuria (ADHH). The genetic link between FBHH and a more serious hypercalcaemia, neonatal severe hyperparathyroidism (NSHPT), may be due to loss-of-function mutations in homozygous form. Another mutation in the CaSR gene may cause familial hypercalcaemia and hypercalciuria with adult onset, associated with a clinical condition very similar to sporadic primary hyperparathyroidism (PHPT). A common polymorphism resulting in a changed amino acid in the intracellular tail of the CaSR, A986S may have a modest e¡ect on serum calcium concentration in healthy individuals.
It can be challenging in the clinical setting to distinguish FBHH from PHPT and ADHH from idiopathic hypoparathyroidism (IHP), because of the common biochemical features. Nevertheless, it is important to make this distinction since clinical management may be dependent on knowledge of the underlying pathophysiology.
This review considers epidemiological, clinical and laboratory features of CaSR disorders, concluding in evidence-based guidelines for diagnostic tests. The current molecular biological basis for the di¡erent clinical conditions is also discussed. The review was conducted in a systematic fashion. Details on the performance of the literature search are in the appendix to this paper and the original data from papers used to inform the review can be found on the Association of Clinical Biochemists' website.
Familial benign hypocalciuric hypercalcaemia
In 1972, a family was described in which 12 members in four generations were hypercalcaemic but lacked the symptoms and signs of altered calcium metabolism. The condition was named familial benign hypercalcaemia. 1 Later studies veri¢ed that this is a syndrome clearly di¡erent from familial endocrine neoplasia and primary hyperparathyroid hyperplasia, 2 and it has become an important consideration in the di¡erential diagnosis of hypercalcaemia. An alternative term for the same condition, familial hypocalciuric hypercalcaemia, has become popular. The two terms may be combined as familial benign hypocalciuric hypercalcaemia. The characteristics of FBHH may be considered as:
. Persistent, non-progressive mild to moderate hypercalcaemia . Relative hypocalciuria . Hypercalcaemia within a family, consistent with autosomal dominant inheritance or presence of an inactivating mutation in the CaSR gene in a hypercalcaemic patient . Absence of classical clinical features of PHPT . Failure of parathyroidectomy to normalize serum calcium concentration in any a¡ected family members who have had surgery.
Epidemiology
To our knowledge, there has been no study which has systematically addressed the issue of prevalence of FBHH in the general population. Estimates of prevalence have been made in three ways. In a tertiary referral centre in the USA, family studies in 103 patients with histologically con¢rmed parathyroid hyperplasia (as opposed to adenoma) demonstrated FBHH in 13 patients. 3 Around 20% of cases of surgical hyperparathyroidism have multiple gland involvement, 4 and so we may estimate that 1 in 40 cases referred for parathyroid surgery has FBHH. Another study from the USA identi¢ed only two cases of FBHH in a consecutive series of 181 operations for PHPT, by close investigation of ¢ve cases in which there was failure to restore normocalcaemia. 5 Two prospective studies of unselected patients referred for investigation of hypercalcaemia have been reported (see Table 1 ). 6, 7 In each study, all new cases of hypercalcaemia were systematically investigated over a 3-year period. Taken together, these show seven new index cases of FBHH per100 cases of surgically proven PHPT. In each study, an unspeci¢ed number of hypercalcaemic cases remained undiagnosed. It is possible that the seemingly greater incidence of PHPT in the Scottish study was due to the new availability of intact molecule PTH assays in the late 1980s, which gave greater con¢dence in the diagnosis of PHPT. Any estimate of prevalence or incidence of FBHH compared with PHPT requires taking into account the remarkable changes in the incidence or recognition of PHPT itself. In the USA, after the introduction of serum calcium measurements on automated laboratory analysers in 1974, the incidence of PHPT rose from 15 to 112 per 100 000 person-years in 1975, and then decreased somewhat. Subsequently, despite improved case ascertainment, the incidence continued to fall, until in 1992 it was four per 100 000 person-years. 8 It can also be calculated from Table 1 that the inclusion of the cases of FBHH detected by screening the families of the index case resulted in a minimum estimated population prevalence of one in 31250 in Australia and one in 15 625 in Scotland. This is considerably greater than the minimum population prevalence estimated from a separate Scottish report in which cases of FBHH were primarily diagnosed following failed parathyroidectomy. 9 
Clinical features of FBHH
Information on the clinical presentation is available for over 300 cases of FBHH. 1,3,4,6,9,10^30 Many of the reports are on small numbers in single families.
Chronic subjective symptoms
Since patients most commonly have biochemical investigations because they present with symptoms, it is not surprising that the index cases of families subsequently shown to have FBHH have had a variety of di¡erent symptoms and possible complications. Table 2 lists studies performed over the past 30 years, each of which have described the clinical presentation of at least 10 a¡ected family members. Some studies (indicated in Table 2 ) have systematically compared the occurrence of symptoms in hypercalcaemic and normocalcaemic subjects.
In 1981, a detailed analysis of 15 kindreds was published. 3 Analysis by telephone, questionnaire and direct interview was conducted with 95 hypercalcaemic and 79 normocalcaemic individuals over a wide age range. Questions were asked about symptoms and signs commonly associated with PHPT, and it was found that a signi¢cantly greater proportion of hypercalcaemic subjects reported symptoms in six of the 10 categories in the survey. However, this study su¡ered from a major potential bias in that both interviewer and interviewees were aware of the serum calcium status of the subjects.
In 1983, 22 hypercalcaemic and 24 normocalcaemic members of a single family were studied by means of a medical consultation or, in ¢ve patients who had had a parathyroidectomy, from the medical notes. 13 Symptoms related to chronic hypercalcaemia (fatigue, depression, myasthenia, abdominal pain, bone and joint pain) were completely absent in nine patients and16 controls. Five patients and two controls regularly experienced marked symptoms, but di¡er-ences were not statistically signi¢cant. Again, all parties were aware of the calcium status of the subjects.
In 1985, the ¢ndings of a series from the Mayo Clinic were published. 15 Eighty-two hypercalcaemic and 52 normocalcaemic adult (age 418 years) members of 15 families were studied by a systematic telephone questionnaire. Muscle weakness, lack of energy, arthralgia and thirst were signi¢cantly more common in subjects with hypercalcaemia. However, in an analysis of those cases found by family screening, no increased prevalence of symptoms was demonstrated. The di¡erences resided only in the index cases, most of whom had had an unsuccessful parathyroidectomy.
In 1986, nine hypercalcaemic and 13 normocalcaemic adult (age 415 years) members of a single family completed a questionnaire addressing 11 possible symptoms. 16 The proband (following unsuccessful parathyroidectomy) complained of painful joints in both hands, and one other a¡ected member complained of constipation. All other a¡ected members were asymptomatic. Only one una¡ected member had symptoms (fatigue, headaches, and abdominal and joint pain). We may conclude that these studies, in which the index case was excluded, failed to show conclusively any di¡erence in symptoms in a¡ected and una¡ected family members.
Acute pancreatitis
For some time it has been thought that there may be a speci¢c association between FBHH and acute pancreatitis. The ¢rst reports were published in 1981. 12, 15 A series of 10 cases was reviewed in 1990, 31 showing that all 10 were index cases and eight had another potential cause of pancreatitis. Since then, a further four cases have been reported, including one man with recurrent pancreatitis over many years of persistent hypercalcaemia and an unsuccessful parathyroidectomy. His hypercalcaemic son had a single episode of pancreatitis in his thirties and no other risk factors were present. 19 Recurrent pancreatitis from age 15 years was reported in a case in which the diagnosis of FBHH was made at age 8 years and there were no other risk factors. 32 In this case, the serum calcium concentration was greater during the ¢rst attack of pancreatitis (3.36 mmol/L) than on any other occasion, and a possible explanation was a large milk intake of up to 2 L/day. The ¢nal reported case was in an 11-year old boy with no other risk factors. 22 This paper provided evidence that cases of FBHH and pancreatitis have the same genetic aetiology as other cases of FBHH. 22 We may conclude that it is not clearly established that FBHH predisposes patients to acute pancreatitis, and that if it does it is a rare occurrence. This is similar to a conclusion reached in a recent review of the occurrence of acute pancreatitis in PHPT. 33 
Nephrolithiasis
We have found a total of 11 cases of nephrolithiasis reported in patients with FBHH. 3,10,13,20^22,29 Eight were the only member of a kindred to su¡er from this problem, and in one family three members were reported, one of whom had a parathyroidectomy resulting in hypocalcaemia. 22 One case had relative hypercalciuria, although other hypercalcaemic members of her family were hypocalciuric. 20 Response to parathyroid surgery in adults A review of surgical experience in FBHH was published in 1986. 16 In a total of 60 parathyroidectomies, only one patient became consistently normocalcaemic post-operatively, six became hypocalcaemic and 53 remained hypercalcaemic. Since then, other reports have con¢rmed this trend. 6, 9, 20, 22, 25, 29 Development of parathyroid adenoma and hyperplasia Systematic searches for CaSR mutations in series of cases of sporadic parathyroid adenoma have yielded negative results, 34 but rarely a parathyroid adenoma and CaSR mutation will occur together.
A report in a meeting abstract 24 described a hypercalcaemic family with variable urinary calcium excretion in three generations. In the ¢rst generation (ages 57 and 58 years), urinary calcium was clearly increased (9.6^11.5 mmol/24 h), in the second generation it was at the upper end of normal (up to 6.5 mmol/24 h) while in the third generation (ages 31 7 years) it was decreased (1.5^4.7 mmol/24 h). Neck exploration in the two oldest members revealed an adenoma in one and hyperplasia of all four glands in another. Following parathyroidectomy, serum calcium became normal in both patients but urine calcium remained elevated. All hypercalcaemic family members had missense mutation S137P in the CaSR gene.
Hypercalcaemia, hypercalciuria, and parathyroid hyperplasia have also been reported in some members of a kindred with an R886P mutation. 29 A further case of parathyroid adenoma was reported in a middle-aged woman with a C562Y mutation and a serum calcium concentration of 4.48 mmol/L. 35 Parathyroidectomy in this case resulted in resolution of hypercalcaemic symptoms and persistence of mild hypercalcaemia.
A Swedish family with 20 a¡ected individuals was described in which a mutation F881L in the region of the CaSR gene coding for the cytoplasmic tail caused hypercalcaemia and hypercalciuria. 36 Subtotal parathyroidectomy revealed parathyroid gland hyperplasia/adenoma and restored normocalcaemia in nine individuals. Thus, the disorder in this family displayed characteristics atypical of FBHH and PHPT.
Taken together, these reports indicate that there are atypical cases of FBHH-like disorders with CaSR mutations, in which the outcome of parathyroid surgery may not be clearly predictable.
Laboratory features of FBHH
In considering the laboratory features of FBHH, the single most important issue is to distinguish the condition from PHPT. There has been no publication which has ful¢lled the Standards for Reporting Diagnostic Accuracy (STARD) criteria, 37 which would require the prospective study (with a full description of analytical methods employed) of a randomly selected cohort of subjects with hypercalcaemia and the performance of tests under investigation and reference standard diagnostic tests in all cases. While the STARD criteria serve as an important checklist for conducting and reporting diagnostic studies, they do not include a method for grading levels of evidence. For this purpose, we used the grades of recommendation used by the Scottish Intercollegiate Guidelines Network (SIGN). Details of the SIGN methodology checklist for diagnostic studies are available elsewhere, 38, 39 but the main gradings are summarized below:
Grade A^At least one meta-analysis, systematic review or randomized controlled trial rated as high quality with a very low risk of bias, and directly applicable to the target population.
Grade B^A body of evidence including high quality case-control or cohort studies with a very low risk of confounding, bias or chance, directly applicable to the target population and demonstrating overall consistency of results.
Grade C^A body of evidence including well conducted case-control or cohort studies with a low risk of confounding, bias or chance, directly applicable to the target population and demonstrating overall consistency of results.
Grade D^Case reports, case series and expert opinion.
The evidence described in this section comes from well conducted (as opposed to high quality) case series, case-control studies and cohort studies, which together demonstrate consistency of results. We therefore consider the evidence to be grade C.
Our literature search found 51 papers in which results of biochemical tests in FBHH were reported.We narrowed this down to 14 publications in which at least 10 cases of FBHH were included in the analysis. In two of these, 15, 16 results were presented in terms of mean, range and standard error and so did not allow the accumulation of individual values for metaanalysis. In one paper, 40 individual values were plotted but interspersed with data from other studies and so it was also excluded. One further paper was excluded because the mutation identi¢ed was a rare variant rather than a CaSR mutation. 41 The ranges of results from these four excluded papers appeared very similar to those found in our meta-analysis.
The meta-analysis was performed using data from the remaining 10 papers. The numbers of subjects from each study, with the range and median of the six most commonly studied biochemical parameters overall, are summarized in Table 3 . Of the 10 studies, three were of a single large kindred, 1, 13, 18 ¢ve consisted of series of cases of FBHH and PHPT collected separately over unspeci¢ed time periods, 3, 9, 12, 42, 43 and two were prospective studies of unselected cases of hypercalcaemia over a 3-year period in the same hospital. 6, 7 A spreadsheet containing the original data from these studies is available at www.acb.org.uk/annclinbiochem/ webwise/ADHHClinBiochem.xls and www.acb.org.uk/ annclinbiochem/webwise/FBHHCalciumdata.xls Table 4 summarizes data for the six most commonly measured biochemical parameters. No attempt has been made to allow for analytical method-related di¡erences in the di¡erent studies, with the exception of the inclusion of only 'intact molecule' parathyroid hormone results. No single test can e¡ectively distinguish FBHH from PHPT. However, the data are presented in such a way that we can derive appropriate action limits to guide us. For example, for serum intact PTH, a concentration of less than 3.0 pmol/L will make FBHH highly probable (assuming other causes of hypercalcaemia, such as neoplasia, hypervitaminosis D, sarcoidosis and hyperthyroidism, have been excluded) and a result of more than 8.5 pmol/L will make PHPT highly probable. Results between 3.0 and 8.5 pmol/L are less helpful. Action limits for 99% sensitivity and speci¢city as well as for 95% sensitivity and speci¢city are presented for each parameter. Given the relatively small number of patients in the metaanalysis, the 99% action limits may give more con¢-dence in reaching a diagnosis. For urine calcium:-creatinine clearance ratio, an additional action limit of 0.01has been included in the analysis since it has been consistently quoted as appropriate. 15, 44 The metaanalysis shows that a result of less than 0.01 will have a sensitivity of 81% for diagnosing FBHH, with a speci¢city of 88% for excluding PHPT.
The meta-analysis does not provide solid evidence for the superiority of any parameter in distinguishing the two conditions. At the 95% sensitivity and speci¢-city level, the best single test appears to be calcium excretion (Ca E ), which is measured on a second-void spot urine and blood sample after an overnight fast, and multiplying the urine calcium:creatinine ratio (both in mmol/L) by the serum creatinine in mmol/L. Theoretically, this may be superior to other tests of urine calcium excretion. Twenty-four-hour urine calcium excretion is a¡ected by variation in dietary calcium intake, and, as Table 3 shows, some studies used calcium-restricted diets while assessing this parameter while others employed a free calcium diet. The calcium:creatinine clearance ratio requires four laboratory measurements, all susceptible to analytical variation, instead of the three used in Ca E . The extra measured parameter, serum calcium, rarely exceeds 3.2 mmol/L in FBHH. 1, 6, 7, 9, 12, 13, 18, 29, 43 In two early extensive reviews, 3, 15 occasional values up to 3.5 mmol/L were reported. Therefore, serum calcium may have higher values in PHPT than in FBHH 6, 7 and result in a lower calcium:creatinine clearance ratio in some cases, and thus a greater overlap in results.
While we could not ¢nd reports of multiple discriminate function analysis, there is evidence that a plot of Ca E against serum PTH can provide greater diagnostic accuracy, 6, 7 because subjects with FBHH have a lower median Ca E and PTH than those with PHPT and so will tend to cluster in a group near the origin of the graph.
Medications such as diuretics can alter urinary calcium excretion and should be discontinued for two months before testing takes place. Acute and chronic studies have shown a signi¢cant hypercalciuric e¡ect of alcohol, a factor held responsible for relative hypercalciuria in at least one case of FBHH. 45 There is also evidence that patients with type 1 diabetes have increased urinary calcium excretion, 7, 46 and so care should be taken when evaluating diabetic patients with hypercalcaemia. Chronic lithium therapy also causes a clear alteration in the dynamics of PTH secretion. 47 There are no data to validate the use of the action limits in Table 4 in patients with renal impairment or vitamin D de¢ciency.
Genetic studies in FBHH
The ¢rst identi¢cation of missense mutations in the CaSR gene causing FBHH was reported in1993. 48 Over 40 di¡erent loss-of-function mutations have now been described, including one in a Swedish family, which caused hypercalcaemia and hypercalciuria. 36 Almost every time a new kindred with FBHH is investigated, a new mutation is found which segregates with hypercalcaemic individuals in that kindred. There are only a few examples of the same loss of activity mutation found in apparently unrelated families: P55L, 49 50 Explanations of how mutations a¡ect function are related to the mechanism of action of the protein, which as yet is not fully elucidated. The protein can be present on the cell as a dimer, 54 which further complicates understanding of the heterozygous state in human tissues, as dominant negative mutations may have more opportunity to exert a major in£uence. Mutations resulting in loss of function are found in the regions coding for extracellular, transmembrane and intracellular domains. Most mutations are missense, replacing one amino acid with another, and there are also two nonsense mutations, a mutation within an intron which a¡ects a splice site, and insertion mutations (see www.casrdb.mcgill.ca/). To convert PTH from pmol/L to ng/L, multiply by 9.5. Ca:creatinine clearance ¼ urine Ca/urine creatinine6serum creatinine/serum Ca, performed on blood sample and random or 24-h urine specimen. Ca E ¼ urine Ca (mmol/L)/urine creatinine (mmol/L)6serum creatinine (mmol/L), performed on blood sample and second-void urine after overnight fast. PTH ¼ parathyroid hormone; TMP ¼ tubular maximum for phosphate; GFR ¼ glomerular filtration rate.
Due to the variety of mutations causing FBHH and our current inability to forecast the e¡ect of any given mutation, detection of a mutation cannot be regarded as de¢nite 'proof' of FBHH (or, indeed, of NSPHT or ADHH). For mutation detection, one strategy to diagnose FBHH would be to sequence the CaSR gene from a hypercalcaemic family member. To avoid the cost of direct sequencing, and also for speed and convenience, screening methods such as denaturing gradient gel electrophoresis or single-strand con¢rmation polymorphism may be employed, although the latter will detect only 70-80% of mutations which can be identi¢ed by gene sequencing. For formal proof of cause and e¡ect, for any CaSR mutations found which have not been described previously in the literature, the sensitivityof the mutant CaSR to calcium should be assessed in vitro (as has been done for over half the FBHH mutations detected) by measuring intracellular calcium responses to changes in extracellular calcium using transiently transfected HEK 293 cells or Xenopus oocytes (see www.casrdb.mcgill.ca/). These measurements require a specialist laboratory, and it may be a reasonable assumption that the presence of a nonsynonymous mutation is responsible for hypercalcaemia in a patient undergoing investigation, especially if it co-segregates in the family (for example, a new mutation found in exon 6). 55 In one-third of FBHH patients, a CaSR gene mutation has not yet been detected. This may be in part due to limitations in the mutation detection methodology used. The disease could be due to mutations in portions of the CaSR gene, 5 0 regulatory regions or introns not normally included in a sequencing screen. In rare cases, a gene other than CaSR is involved. There exists a rare variant of FBHH observed in a family in Oklahoma, which appears to be due to a mutation of another gene, probably on chromosome 19. 56 A syndrome with the biochemical picture of FBHH has recently been described in patients with anti-CaSR autoantibodies and associated autoimmune disorders such as coeliac disease or thyroid disease. 57 The antiCaSR antibodies may interfere with calcium-mediated suppression of PTH release and perturb calciumsensing in the kidney, thereby mimicking FBHH. Since this syndrome may be an acquired rather than an inherited disorder present from birth, it is possible that the clinical sequelae may di¡er from those of cases with CaSR gene mutations. However, only four individuals in two families have been described to date.
Neonatal severe hyperparathyroidism
Neonatal severe hyperparathyroidism is a very rare condition. It can be de¢ned as symptomatic hypercalcaemia with hyperparathyroid bone disease occurring in children under 6 months of age. Its association with FBHH was ¢rst noted in 1982. 58 In a review of the literature up until 1994, a total of 49 cases was identi¢ed. 59 Many, but not all, of these could be shown to be members of families with FBHH. In 41 cases in which parathyroid tissue was removed at surgery or postmortem, multiple parathyroid glands were a¡ected by hyperplasia. No case of single parathyroid adenoma was found.
Clinical features of NSHPT
Neonatal severe hyperparathyroidism is generally manifest in the ¢rst few days of life with failure to thrive, hypotonia, constipation and respiratory distress. Typical bone abnormalities are undermineralization, rib cage deformity, and subperiosteal erosions and metaphyseal widening of the long bones. Many of the initial cases died, or survived following total parathyroidectomy which rendered them hypoparathyroid. However, particularly in less severe cases, conservative management can result in considerable improvement, with eventual resolution of symptoms and normal development. Heath 59,60 compared cases reported pre-1982 and those reported afterwards. In 25 early cases, only 12.5% of patients managed conservatively survived, compared with a 73.3% survival following parathyroidectomy. Of the 24 cases reported from 1982 to 1994, only two died, both following surgery. All seven cases managed medically survived, although they had a milder degree of hypercalcaemia (up to 3.18 mmol/L). It may be that earlier recognition of hypercalcaemia, together with prompt £uid replacement and the use of e¡ective drugs to control hypercalcaemia, have contributed to the improved survival with medical management.
Pearce and Steinmann 61 summarized a rational approach to management in a case of a neonate presenting with hypercalcaemia, bony undermineralization, subperiosteal erosions and fractures. Respiratory failure, extreme hypercalcaemia and failure to thrive are all indications for early parathyroidectomy.
Successful heterotopic autotransplantation of parathyroid tissue into the forearm 45 or the quadriceps 62 has been described and may aid in achieving long-term normal serum calcium. In the future, it is possible that calcimimetic compounds, highly speci¢c calcium agonists which activate the CaSR receptor, may have a role in the management of NSHPT. 63 
Laboratory tests in NSHPT
Serum calcium concentration in NSHPT can range from 2.73 mmol/L 64 to 7.1mmol/L. 58 Characteristically, there is a very high serum PTH, 61, 65 but rarely the PTH is in the reference range. 53 Parameters of urine calcium excretion may be low 45 53, 64 but may be in the reference range. 69 Demonstration of hypercalcaemia in one or both parents in an infant with NSHPT will point strongly towards the presence of a CaSR-inactivating mutation in the child. However, such a mutation can occur when both parents are normocalcaemic, either because the mutation was de novo in the child, 53 or because hypercalcaemia in the parent(s) is mild and intermittent. 66 
Genetic studies in NSHPT
Most NSHPT can be explained by homozygosity for loss-of-function mutations in the CaSR gene. 48, 49, 51, 70 A case with compound heterozygous mutations has also been reported. 67 However, this disease has variable expression and on investigation of the family it is not unusual to ¢nd that only one parent (usually the father) has FBHH. 61 There are also cases in which neither parent has FBHH but the de novo mutation is su⁄ciently severe and dominant to produce the symptoms, e.g. the R185Q mutation. 53 Three cases of moderate-to-severe hypercalcaemia presenting in adulthood, but due to homozygous lossof-function mutations of the CaSR gene, have been reported. 25, 71, 72 None had clinical parathyroid disease as adults, but all three had severe mental retardation, suggesting that early intervention with parathyroidectomy may have been bene¢cial. One of the three cases had total parathyroidectomy at age 26 years, but no clinical improvement resulted. 25 Serum calcium concentration in the three cases ranged from 3.00 to 4.29 mmol/L; PTH was elevated in two cases but normal in the other. Urine calcium:creatinine clearance ratio was low, ranging from 0.003 to 0.008.
Other neonatal consequences in families with FBHH
Where a case of NSHPT occurs in an infant with a normocalcaemic mother and a hypercalcaemic father, it may be postulated that hyperparathyroidism would develop in utero because the fetus would missense the concentration of calcium being transported across the placenta from the mother as being hypocalcaemic. After delivery, the hyperparathyroidism would gradually resolve, with healing of any associated metabolic bone disease. This otherwise attractive explanation fails to account for the occurrence of NSHPT in only a small minority of cases of FBHH in which the father and baby have a heterozygous mutation.
Conversely, there have been descriptions of symptomatic hypocalcaemia in neonates born to parents of whom the father is normocalcaemic and the mother has FBHH. 69, 73, 74 In one of these cases, the infant had low serum magnesium of 0.16 mmol/L in a family with the Oklahoma FBHH variant. 73 In the others, there was no report of serum magnesium or genetic analysis, but the diagnostic criteria were otherwise satisfactory for FBHH.
To our knowledge, there has been no study which has systematically measured serum calcium in the newborn of FBHH subjects, whether father or mother was the a¡ected parent.
Activating mutations of CaSR gene
Inherited forms of hypoparathyroidism have long been recognized. In 1987, a form of autosomal dominant hypoparathyroidism was described in a family containing several hypocalcaemic individuals lacking clear symptoms or signs of hypocalcaemia. 75 As it became clear that loss of CaSR function could cause FBHH, it was speculated that inappropriate activation of the CaSR could lead to hypocalcaemia. In 1994 came the ¢rst published description of a mutation in the CaSR gene, E127A, causing a form of autosomal dominant hypocalcaemia. 76 This syndrome is associated with relative hypercalciuria and can be regarded as a 'mirror image' of FBHH. In most publications, the term 'autosomal dominant hypocalcaemia' has been used when referring to the syndrome, but more recently 'autosomal dominant hypocalcaemia with hypercalciuria' (ADHH) has been proposed.
Historically, hypoparathyroidism of unknown aetiology has been called idiopathic hypoparathyroidism. However, many cases labelled IHP in the past may actually be due to CaSR-activating mutations. The picture is further complicated by the ¢nding of de novo CaSR-activating mutations 77^81 which may give rise to a similar clinical and biochemical pattern to ADHH without the presence of a clear family history consistent with autosomal dominant inheritance.
Epidemiology
Although there has been no extensive survey designed to measure the prevalence of gain-of-function CaSR mutations, there have been population studies of the prevalence of IHP. Between 1959 and 1965 in the USA, screening of 25 847 adults by measuring serum calcium in patients referred to a general medical clinic for reasons other than calcium-related disorders revealed two cases of IHP. 82 In Sweden, a screen between 1971 and 1973 of 15 903 council employees revealed no cases of IHP. 83 In the USA between January 1978 and July 1979, analysis of 108 000 automated biochemical pro¢les and follow-up of hypocalcaemic results found two cases of IHP. 84 It is likely that these studies underestimate the true prevalence of IHP, which may present in infancy and result in treatment with vitamin D, which would have excluded patients from participation. Once the genetic basis of ADHH was known, it became apparent that many cases previously labelled IHP were in fact due to CaSRactivating mutations. In one study of19 cases of IHP in Japan, 79 eight were shown to have such a mutation.We can therefore estimate that, although a rare condition, ADHH may occur in around one in 70 000 of the population, perhaps a slightly lower prevalence rate than for FBHH.
Clinical features of ADHH
In the ¢rst description, in 1994, of a missense activating CaSR mutation causing ADHH, 13 of 14 members of the kindred were asymptomatic at diagnosis. 76 The remaining individual experienced intermittent overt tetany. Since that report, a number of papers which include clinical details of subjects with gain-of-function mutations in the CaSR gene have been published. 77^81,85^99 We could ¢nd only two papers reporting a systematic examination of the clinical features and management of the condition in more than seven cases.
In the ¢rst of these, 85 six kindreds were selected on the basis of hypocalcaemia with isolated hypoparathyroidism but serum PTH within the range expected in normocalcaemic subjects. Twenty of 37 family members studied had hypocalcaemia. At the time of diagnosis, nine were asymptomatic. Eleven had carpopedal spasm or childhood seizures, two of these also having basal ganglia calci¢cation on radiological examination. In one subject, seizures continued into adult life. Treatment of 19 subjects with oral preparations of vitamin D resulted in nephrocalcinosis on radiological examination in 11 cases, renal impairment (serum creatinine 4135 mmol/L) in 14 cases (reversed on stopping vitamin D therapy in four cases) and nephrolithiasis in four cases. In all cases in which it was measured, there was an increase in urinary calcium excretion during therapy.
In the second study, 79 CaSR mutations were identi¢ed in eight of 19 unrelated cases of isolated hypoparathyroidism. Family studies of these eight individuals revealed apparent de novo mutations in four, and a pattern consistent with autosomal dominant inheritance of hypocalcaemia in the other four. A further 13 cases were identi¢ed in the four kindreds, and so 21 hypocalcaemic individuals were studied. Of these, seven were asymptomatic, eight presented with mild symptoms of hypocalcaemia (paraesthesiae, muscle cramps, neuromuscular irritability and/or carpopedal spasm) and six (including the four de novo cases) were severely a¡ected, having recurrent seizures requiring emergency treatment with calcium and vitamin D. The presence of symptoms was clearly related to the degree of hypocalcaemia^severe symptoms occurring within a range of serum calcium from 1.20^1.75 mmol/L, mild symptoms from 1.501 .95 mmol/L and no symptoms from1.90^2.10 mmol/L. Fourteen patients were treated with 1-hydroxylated derivatives of vitamin D3 for a mean duration of 7 years. Treatment resulted in resolution of symptoms in all cases and caused signi¢cant increase in serum calcium. Some patients developed hypercalcaemia (up to 4.10 mmol/L on doses of 4 mg/day and up to 3.20 mmol/L on 2.5 mg/day). Renal ultrasound revealed nephrocalcinosis in eight cases, reversible in one case with reduction in the dose of vitamin D. The presence of nephrocalcinosis was clearly related to increased urinary calcium. There were no cases of nephrolithiasis or elevated serum creatinine. This study included one man aged 50 years who was homozygous for a mutation causing a large deletion within the intracellular tail of the CaSR and who had only mild clinical symptoms.
Of the 11 cases of de novo CaSR-activating mutations, 77^81 ten were diagnosed in neonates or infants with severe symptoms due to hypocalcaemia, and the remaining one, with mild symptoms, at age18 years. It is tempting to speculate that de novo mutations are more likely to cause symptoms than autosomal dominantly inherited mutations, but these ¢ndings could be explained by ascertainment bias^we could ¢nd only one study that has systematically sought CaSR mutations in 19 cases of IHP, 79 in a group which included at most 14 adults.
There have been other reports of calci¢cation of the basal ganglia in ADHH, 77, 78, 86, 93, 96, 98 and one case of intracerebral calci¢cation, 91 but the clinical signi¢-cance of these is uncertain.
Other clinical features which have been reported with ADHH include impaired cardiac function which improves with the relief of hypocalcaemia, 98,100 a type of Bartter's syndrome, 81, 94 and osteoarthritis. 88 The relatively high rates of hypercalciuria, nephrocalcinosis and renal impairment following vitamin D therapy are a cause for concern in the management of ADHH. These complications can also occur during vitamin D treatment in idiopathic and other causes of hypoparathyroidism, 101 but there is a strong perception that the likelihood is greater in ADHH. It is di⁄-cult to be dogmatic about this, because if the study of Leinhardt et al. 79 is representative of the hypoparathyroid population as a whole then a large number of cases previously diagnosed as IHP will in fact be autosomal dominant or de novo cases of activating mutations of CaSR. A pragmatic approach to the management of ADHH has been outlined by Leinhardt et al. 79 They suggest that all severely symptomatic patients should be treated with vitamin D, but the decision to initiate treatment should be carefully evaluated on a case-by-case basis in asymptomatic or mildly symptomatic patients. Once treatment is initiated, the dose of 1-hydroxylated vitamin D preparations should be kept as low as possible, and the patients closely monitored to avoid prolonged episodes of hypercalciuria. There is evidence that a combination of low-dose 1-hydroxylated vitamin D and thiazide diuretics can successfully achieve the goals of therapy in patients with CaSR-activating mutations. 80, 102 The use of thiazides has also been described in the management of patients with IHP. 103 
Laboratory features of ADHH
A number of papers have provided information on results of biochemical analysis in patients with CaSRactivating mutations.
52,76^79,81,85,87^90,93^98 Table 5 summarizes the numbers studied, medians and ranges of the ¢ve biochemical parameters for which at least 20 individual datapoints are available in patients prior to instigation of vitamin D therapy from these studies. Serum phosphate is divided into adult and pre-adult categories because of the di¡erent reference ranges with this parameter. The lowest value of serum calcium is 1.20 mmol/L, while concentrations as low as 0.90 mmol/L are seen in IHP. 104 A recent review stated that ADHH patients 'almost invariably' had signi¢cant hypomagnesaemia, 105 but only 27 of 38 patients in our meta-analysis had serum magnesium 40.70 mmol/L. Thirty-one of 47 subjects had a serum intact PTH of 1.0 pmol/L or more, a concentration which is thought to be unlikely in IHP. Nevertheless, we could ¢nd no published work in which there was a systematic comparison of serum magnesium, intact PTH or phosphate in both ADHH and IHP patients. The Ca E measurement, useful in the diagnosis of FBHH, has not been reported in papers describing biochemical parameters in ADHH.
One paper 104 reported measurements of calcium: creatinine ratio in a random urine specimen in 57 patients with IHP obtained from a Japan-wide collaborative study, compared with four patients with CaSR-activating mutations. We have added to this a further 22 measurements of random urine calcium: creatinine ratio in activating mutations, from other published work, 85,87,93,94,96^98 and analysed the cumulative data. In patients with CaSR-activating mutations, the median ratio was 0.37 with a range of 0.03 to 0.82 (seeTable 5). In patients with IHP, the median was 0.09 with a range of 0.01 to 0.31. Only two of 57 patients with IHP, but 18 of 26 cases of CaSRactivating mutations, had a ratio of greater than 0.30.
It has been suggested that commencement of vitamin D therapy leads to a higher urine calcium: creatinine ratio in ADHH than in IHP, 105 but the data from the Japanese study 104 do not con¢rm this.
Genetic studies in ADHH
So far, over 25 gain-of-function mutations causing ADHH have been described. Nearly all are missense mutations in either the extracellular region or the transmembrane region of the CaSR. There is one gainof-function mutation with an in-frame deletion in the carboxy terminal tail of the protein. 48 Most mutations are family-speci¢c, the few recurring ones being T151M, 85,106,107 N118K 78,85 and F612S. 85, 108 When reading the literature, it is important to be aware that there is some lack of consistency as to the naming of these conditions, for example, LÖvlie et al. 106 clearly refer to the calcium-sensing receptor gene gain of function but call the condition of the proband autosomal dominant hypoparathyroidism instead of autosomal dominant hypocalcaemia with hypercalciuria. De Luca et al. 78 identi¢ed a gain-of-function mutation in a family, but because the mutation happened de novo they referred to the proband as having 'sporadic hypoparathyroidism'. Genetically, these conditions are the same. The molecular mechanism for the activation of the receptor is not understood, but it is not surprising that none of the gain-of-function mutations can be explained by stop codons inappropriately terminating the protein synthesis. About half of the described mutations have been tested in the in vitro system described in the FBHH section and have been shown to activate the receptor. 
Polymorphic variants of CaSR gene
Some mutations in the CaSR gene are so common in certain populations that they can be described as polymorphisms. Two of these which have been the subject of a number of studies are A986S and G990R, which are single-nucleotide polymorphisms on exon 7, which encodes the intracellular domain of the CaSR. The S986 variant of the A986S polymorphism has an allele frequency of around15% in the populations of Europe, North America and New Zealand 29,50,109^116 but is very rare in Japan. 96,117^120 There is some evidence that subjects with the S986 variant have higher mean serum calcium than those without, 110, 111, 113 particularly in the 3^5% of subjects who are S986-homozygous. 110 Other reports do not con¢rm this trend. 112, 114, 116 If there is mild hypercalcaemia due to a polymorphic variant in the CaSR gene, this may have implications in the distinction between FBHH and PHPT. To complicate matters further, one small study from Germany reported that six out of nine men with PHPT had the S986 allele, compared with 13 of 56 healthy controls. 111 The higher S986 frequency was not found in female patients or in other studies with mixed-gender groups. 34, 114 The R990 variant of the G990R polymorphism is the predominant allele in most studies from Europe and North America, with allele frequencies of 879 9%. 109^114 One study from the USA appears to show the opposite e¡ect, with a frequency of 15%. 50 In Japan, the reported R990 allele frequency ranges from 32^44%.
96,118^120
One Japanese mother and daughter had the G990 variant and clinical features of FBHH, 118 but we could ¢nd no other reports of alterations in serum calcium in subjects with G990R polymorphisms. One Italian study noted an increased frequency of the R990 variant in hypercalciuric stone-formers compared with normocalcaemic controls, 113 but this ¢nding was not con¢rmed in a Canadian study. 121 There is no record in the literature of attempts to detect di¡erences in the in vitro assay using transfection into HEK cells, presumably because the predicted small di¡erences in calcium set-point would be undetectable by this assay.
Further work would be necessary to clarify whether A986S and G990R polymorphisms cause signi¢cant variations in serum and urine calcium, or are risk factors for the development of PHPTor nephrolithiasis.
Evidence-based diagnostic guidelines FBHH (Grade C evidence, as described earlier in this paper.)
After a family is found to have FBHH, the diagnosis of family members found to be hypercalcaemic is straightforward. To identify new index cases and to clearly separate them from cases of PHPT is a greater challenge. Although there are many other causes of hypercalcaemia, all of these are likely to show an intact PTH concentration of less than 3.0 pmol/L and so there is little risk of confusion with PHPT.
Over the past decade or more, there has been an increasing tendency to pursue conservative management for asymptomatic PHPT, a situation which applies to the majority of cases. If a conservative policy is followed for asymptomatic PHPT then failing to diagnose FBHH will not harm the patient, whereas misdiagnosing FBHH as PHPT and performing an unnecessary neck exploration is a serious consequence.
The diagnostic guideline for diagnosis of FBHH outlined in Fig. 1 takes the above consideration into account. First-line testing with serum intact PTH will e¡ectively exclude PHPT if the result is less than 3.0 pmol/L and con¢rm it if above 8.5 pmol/L. For values from 3.0^8.5 pmol/L, further investigation may take place only if therapeutic intervention for PHPT will be actively pursued. Then, a combination of a family screen, serum magnesium and a fasting (second-void) urine for Ca E will result in ¢rm diagnosis in many cases. The use of ionized calcium to detect mild degrees of hypercalcaemia in relatives may be helpful. Types of familial hyperparathyroidism other than FBHH may have hypercalcaemic ¢rst-degree relatives but will lack the other biochemical features of FBHH. Where doubt remains, sequencing of the CaSR gene for inactivating mutations may be undertaken. It is likely that this will be required in only a small minority of cases.
Conservative management of PHPT should include assessing the risk of osteoporosis and monitoring renal function.
ADHH
(This evidence is considered grade D, as it is based upon case series and reports.)
A signi¢cant proportion of cases formerly diagnosed as IHP are actually due to CaSR-activating mutations, some inherited in autosomal dominant fashion, and some occurring de novo. There is thus uncertainty in making a distinction between clinical and biochemical features of the two conditions. Figure 2 is a summary of a guideline which may be used to diagnose CaSR-activating mutation cases. It assumes that other causes of hypocalcaemia (such as vitamin D de¢ciency, renal impairment, post-surgical hypoparathyroidism, profound hypomagnesaemia and pluriglandular autoimmune hypoparathyroidism) have already been excluded.
A serum calcium concentration of less than 1.20 mmol/L virtually excludes a CaSR mutation. Serum magnesium below 0.70 mmol/L, PTH between 1.0 and 3.5 pmol/L, and a urine calcium:creatinine ratio of greater than 0.30 mmol/mmol are all suggestive of a CaSR mutation case, but in many cases the results will not fall into these ranges. Di¡erentiation between ADHH and IHP may be di⁄cult, and often impossible, without sequencing the CaSR gene.
In practical terms, it may not be of great importance for the management of the individual patient to make the distinction between ADHH and IHP. It remains unclear whether treatment with vitamin D therapy should be given at all in asymptomatic cases.When it is given, the aim of therapy is to prevent the occurrence { Ca E 414 mmol/L GF suggests FBHH (also plot Ca E against PTH 7 ), and Ca E 527 mmol/L GF suggests PHPT. Ca E ¼ urine Ca (mmol/L)/urine creatinine (mmol/L)6serum creatinine (mmol/L) in fasting blood sample and second-void fasting urine. Diabetes and ethanol use can increase Ca E . Diuretics should be discontinued for 2 months prior to testing. Lithium may also alter parameters of Ca homeostasis. PTH ¼ parathyroid hormone; GF ¼ glomerular filtrate.
of further symptoms by maintaining serum calcium concentration below or in the lower part of the reference range, at a level which does not cause hypercalciuria. These objectives would apply to the treatment of ADHH and IHP.
Conclusion
In the past 10 years, disorders of the calcium-sensing receptor caused by mutations in the CaSR gene have been recognized and increasingly well de¢ned and characterized. Careful clinical assessment combined with biochemical testing and family studies will result in a con¢dent diagnosis in many cases of hypercalcaemia due to FBHH or NSHPT, and hypocalcaemia due to ADHH. A lack of high quality studies of diagnostic biochemical tests has contributed to the diagnostic uncertainty in other cases, particularly where family studies are unavailable or unhelpful. Genetic analysis for activating and inactivating mutations in the CaSR gene is available but is resource-intensive and may not detect a mutation in all cases. In clinical practice, genetic analysis should be reserved for the rare cases in which detection of a mutation will in£u-ence the management and monitoring of the patient.
